Phase II-III
Efficacy & Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis
- Study HIC#:2000026943
- Last Updated:01/01/0001
Yale is participating in this phase III research study that is testing a new medication (Risankziumab) for Ulcerative Colitis (UC)
You may qualify if you:
- Are between the ages of 18-80
- Have been diagnosed with UC within the past 90 days
- Are currently having UC symptoms
- Have tried medication for UC but still have symptoms
- Age16 years - 80 years
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Elizabeth Ruggiero
- Phone Number: 1-203-785-4576
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
You may qualify if you:
- Are between the ages of 18-80
- Have been diagnosed with UC within the past 90 days
- Are currently having UC symptoms
- Have tried medication for UC but still have symptoms
